Caribou Biosciences (CRBU) Accounts Payables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accounts Payables data on file, last reported at $3.5 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.5 million, down 9.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 9.55% YoY), and the FY2025 annual result was $5.8 million, up 133.56% from the prior year.
• Accounts Payables declined to $3.5 million in Q1 2026 per CRBU's latest filing, from $5.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $5.9 million in Q1 2024 and troughed at $426000.0 in Q2 2022.
• A 5-year average of $3.0 million and a median of $3.1 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 89.43% in 2022, then soared 940.61% in 2023.
• A 5-year view of Accounts Payables shows it stood at $1.1 million in 2022, then jumped by 172.25% to $3.1 million in 2023, then dropped by 20.64% to $2.5 million in 2024, then soared by 133.56% to $5.8 million in 2025, then sank by 39.43% to $3.5 million in 2026.
• Business Quant data shows CRBU's Accounts Payables at $3.5 million in Q1 2026, $5.8 million in Q4 2025, and $3.8 million in Q3 2025.